RESUMEN
AIMS: Flavanol-rich chocolate (FRC) is beneficial for vascular and platelet function by increasing nitric oxide bioavailability and decreasing oxidative stress. Congestive heart failure (CHF) is characterized by impaired endothelial and increased platelet reactivity. As statins are ineffective in CHF, alternative therapies are a clinical need. We therefore investigated whether FRC might improve cardiovascular function in patients with CHF. METHODS AND RESULTS: Twenty patients with CHF were enrolled in a double-blind, randomized placebo-controlled trial, comparing the effect of commercially available FRC with cocoa-liquor-free control chocolate (CC) on endothelial and platelet function in the short term (2 h after ingestion of a chocolate bar) and long term (4 weeks, two chocolate bars/day). Endothelial function was assessed non-invasively by flow-mediated vasodilatation of the brachial artery. Flow-mediated vasodilatation significantly improved from 4.98 ± 1.95 to 5.98 ± 2.32% (P = 0.045 and 0.02 for between-group changes) 2h after intake of FRC to 6.86 ± 1.76% after 4 weeks of daily intake (P = 0.03 and 0.004 for between groups). No effect on endothelial-independent vasodilatation was observed. Platelet adhesion significantly decreased from 3.9 ± 1.3 to 3.0 ± 1.3% (P = 0.03 and 0.05 for between groups) 2 h after FRC, an effect that was not sustained at 2 and 4 weeks. Cocoa-liquor-free CC had no effect, either on endothelial function or on platelet function. Blood pressure and heart rate did not change in either group. CONCLUSION: Flavanol-rich chocolate acutely improves vascular function in patients with CHF. A sustained effect was seen after daily consumption over a 4-week period, even after 12 h abstinence. These beneficial effects were paralleled by an inhibition of platelet function in the presence of FRC only.
Asunto(s)
Cacao/fisiología , Dulces , Flavonoles/farmacología , Insuficiencia Cardíaca/fisiopatología , Índice Tobillo Braquial , Barorreflejo/efectos de los fármacos , Biomarcadores/metabolismo , Presión Sanguínea/efectos de los fármacos , Método Doble Ciego , Endotelio Vascular/fisiología , Femenino , Flavonoles/sangre , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Estrés Oxidativo/efectos de los fármacos , Adhesividad Plaquetaria/efectos de los fármacos , Polifenoles/sangre , Vasodilatación/efectos de los fármacosRESUMEN
Epidemiological data demonstrate that regular dietary intake of plant-derived foods and beverages reduces the risk of coronary heart disease and stroke. Among many ingredients, cocoa might be an important mediator. Indeed, recent research demonstrates a beneficial effect of cocoa on blood pressure, insulin resistance, and vascular and platelet function. Although still debated, a range of potential mechanisms through which cocoa might exert its benefits on cardiovascular health have been proposed, including activation of nitric oxide and antioxidant and antiinflammatory effects. This review summarizes the available data on the cardiovascular effects of cocoa, outlines potential mechanisms involved in the response to cocoa, and highlights the potential clinical implications associated with its consumption.
Asunto(s)
Bebidas , Cacao , Cardiopatías/prevención & control , Hipertensión/prevención & control , Fitoterapia , Adulto , Anciano , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Bebidas/efectos adversos , Cacao/efectos adversos , Cacao/química , Catequina/farmacología , Catequina/uso terapéutico , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Femenino , Flavonoides/farmacología , Flavonoides/uso terapéutico , Manipulación de Alimentos , Cardiopatías/epidemiología , Humanos , Hiperlipidemias/dietoterapia , Hiperlipidemias/epidemiología , Hiperlipidemias/prevención & control , Hipertensión/dietoterapia , Hipertensión/epidemiología , Indígenas Centroamericanos , Resistencia a la Insulina , Iowa/epidemiología , Masculino , Medicina Tradicional , Persona de Mediana Edad , Óxido Nítrico/metabolismo , Sobrepeso/etiología , Agregación Plaquetaria/efectos de los fármacos , Suiza/epidemiologíaAsunto(s)
Presión Sanguínea/efectos de los fármacos , Cafeína/farmacología , Estimulantes del Sistema Nervioso Central/efectos adversos , Café/efectos adversos , Infarto del Miocardio/inducido químicamente , Presión Sanguínea/fisiología , Cafeína/sangre , Estudios de Casos y Controles , Conducta Alimentaria , Humanos , Sistema Nervioso Simpático/efectos de los fármacosRESUMEN
The ability to modify the enzymatic processes involved in promoting atherosclerotic plaque disruption and to serially monitor atherosclerotic evolution could provide novel information in the management of patients with atherosclerosis. We studied the effects of a statin (atorvastatin) and its combination with an acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor (avasimibe) on atherosclerotic regression and plaque stability as measured by matrix metalloproteinase 1 and 3 (MMP-1 and MMP-3) levels. Watanabe Heritable Hyperlipidemic (WHHL) rabbits treated with atorvastatin alone experienced an attenuated increase in atherosclerotic burden versus controls as determined by MR imaging. The mean vessel wall area (VWA) prior to drug therapy was 5.57 +/- 0.01 mm2. The VWA increased to 6.71 +/- 0.03 and 7.16 +/- 0.03 mm2, respectively, in atorvastatin-treated and control groups (p < 0.0001 for both). The combination of atorvastatin and avasimibe induced a significant regression of the previously established atherosclerotic lesions, with the VWA decreasing to 4.54 +/- 0.04 mm2 (p = 0.009). Atorvastatin alone induced a nonsignificant reduction in the percent staining of MMP-1 in atherosclerotic lesions, but the combination treatment with avasimibe led to a significant reduction versus controls (p = 0.005). However, a reduction in MMP-3 staining was significant for rabbits treated with both atorvastatin alone (p = 0.007) and in combination with avasimibe (p = 0.04) versus controls. In this animal model, the addition of avasimibe to atorvastatin has beneficial effects on both atherosclerotic plaque regression and stabilization.
Asunto(s)
Acetatos/uso terapéutico , Enfermedades de la Aorta/tratamiento farmacológico , Aterosclerosis/tratamiento farmacológico , Ácidos Heptanoicos/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hiperlipidemias/tratamiento farmacológico , Pirroles/uso terapéutico , Esterol O-Aciltransferasa/antagonistas & inhibidores , Ácidos Sulfónicos/uso terapéutico , Acetamidas , Acetatos/administración & dosificación , Animales , Aorta Abdominal/enzimología , Aorta Abdominal/lesiones , Aorta Abdominal/patología , Enfermedades de la Aorta/enzimología , Enfermedades de la Aorta/etiología , Enfermedades de la Aorta/patología , Aterosclerosis/enzimología , Aterosclerosis/etiología , Aterosclerosis/patología , Aterosclerosis/prevención & control , Atorvastatina , Cateterismo/efectos adversos , Colesterol/sangre , Progresión de la Enfermedad , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Ácidos Heptanoicos/administración & dosificación , Inhibidores de Hidroximetilglutaril-CoA Reductasas/administración & dosificación , Hiperlipidemias/sangre , Hiperlipidemias/complicaciones , Hiperlipidemias/genética , Imagen por Resonancia Magnética , Metaloproteinasa 1 de la Matriz/análisis , Metaloproteinasa 3 de la Matriz/análisis , Pirroles/administración & dosificación , Conejos , Distribución Aleatoria , Sulfonamidas , Ácidos Sulfónicos/administración & dosificaciónRESUMEN
Essential hypertension is associated with enhanced biological activity of endothelin-1 (ET-1) and impaired endothelium-dependent vasodilatation. Dihydropyridine calcium antagonists have antioxidant activity in vitro, and they improve endothelial function in vivo. We tested whether calcium antagonists also influence the biological activity of ET-1 in essential hypertensive (EH) patients in the presence and absence of hypercholesterolemia. In 9 healthy subjects (normotensive [NT] subjects, age: 48.3+/-7.6 years; blood pressure: 118+/-8.6/69+/-5.4 mm Hg) and 21 EH subjects (age: 50.0+/-7.8 years; blood pressure: 164.4+/-5.4/103.8+/-4.4 mm Hg), we studied forearm blood flow and its modification induced by intrabrachial administration of ET-1, phenylephrine, acetylcholine, and sodium nitroprusside at baseline and after 24 weeks of treatment with a nifedipine gastrointestinal therapeutic system (30 to 60 mg per day). At baseline, the first dose of ET-1 (0.5 microg/100 mL of forearm tissue per minute) caused a slight vasodilatation in NT but not in EH subjects, whereas the following higher doses caused a comparable dose-dependent vasoconstriction in EH and NT subjects. The effect of acetylcholine was significantly reduced in EH as compared with NT subjects. In contrast, sodium nitroprusside and phenylephrine had similar effects in NT and EH subjects. After chronic treatment with the nifedipine gastrointestinal therapeutic system, the vasoconstrictor effect induced by both ET-1 and phenylephrine was significantly blunted, whereas the response to acetylcholine was significantly increased and the vasodilation to sodium nitroprusside unchanged. Hypercholesterolemic EH subjects showed a further reduced response to acetylcholine compared with normocholesterolemic EH subjects, and the nifedipine gastrointestinal therapeutic system restored the vasodilation to acetylcholine in this subgroup. In conclusion, in EH subjects, chronic treatment with a long-acting dihydropyridine calcium antagonist not only exhibits a blood pressure-lowering effect but also reduces ET-1-induced vasoconstriction and improves endothelium-dependent vasodilation. Those vasculoprotective effects may importantly contribute to a reduction in major clinical events seen during treatment with these compounds.
Asunto(s)
Bloqueadores de los Canales de Calcio/administración & dosificación , Endotelina-1/farmacología , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Nifedipino/administración & dosificación , Vasoconstricción/efectos de los fármacos , Acetilcolina/administración & dosificación , Acetilcolina/farmacología , Adulto , Arteria Braquial , Bloqueadores de los Canales de Calcio/uso terapéutico , Preparaciones de Acción Retardada , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Endotelina-1/administración & dosificación , Femenino , Antebrazo/irrigación sanguínea , Humanos , Hipercolesterolemia/complicaciones , Hipertensión/complicaciones , Inyecciones Intraarteriales , Masculino , Persona de Mediana Edad , Nifedipino/uso terapéutico , Fenilefrina/administración & dosificación , Fenilefrina/farmacología , Flujo Sanguíneo Regional/efectos de los fármacos , Vasoconstrictores/administración & dosificación , Vasoconstrictores/farmacología , Vasodilatadores/administración & dosificación , Vasodilatadores/farmacologíaRESUMEN
Coffee is widely consumed, especially during mental stress conditions. Cardiovascular impact of coffee remains debated because the underlying mechanisms of action are complex. We reported previously differential cardiovascular stimulation of coffee at rest depending on habitual consumption. The present study was designed to evaluate the effects of coffee on cardiovascular response to mental stress. In 15 healthy volunteers (6 habitual, 9 nonhabitual coffee drinkers), we assessed the effect of mental stress on blood pressure (BP), heart rate (HR), and muscle sympathetic activity (MSA) before and after a triple espresso, intravenous caffeine, and placebo in the same subjects. Under baseline conditions, mental stress significantly increases MSA (+2.5+/-0.7 volts per minute; +14.1+/-10.3%), systolic (+11.6+/-4.1 mm Hg) and diastolic BP (+6.4+/-2.0 mm Hg), and HR (+9.6+/-1.8 minutes(-1)). In nonhabitual coffee drinkers, a triple espresso but not caffeine induced an additional increase in systolic BP (+9+/-6.3 mm Hg; P=0.003) during mental stress, whereas in habitual drinkers, the stress-induced BP increase was blunted (+4+/-3.9 mm Hg; P=NS). As a result, nonhabitual coffee drinkers experienced significantly higher BP during mental stress than habitual drinkers (151+/-17.9/83+/-5.6 mm Hg versus 130+/-7.8/74+/-6.7 mm Hg; P<0.05). Caffeine induced similar effects in habitual and nonhabitual coffee drinkers at rest and during mental stress. The response to the cold pressor test was not influenced by coffee drinking in both groups. In conclusion, in nonhabitual coffee drinkers, coffee enhances the cardiovascular response to mental stress with an additional increase in systolic BP, whereas in habitual drinkers, the response is blunted. Caffeine alone does not exert any potentiating effect, confirming that ingredients other than caffeine are partially responsible for the stimulating effect of coffee on the cardiovascular system.
Asunto(s)
Presión Sanguínea , Café , Ingestión de Líquidos/fisiología , Hábitos , Estrés Psicológico/fisiopatología , Adulto , Presión Sanguínea/efectos de los fármacos , Determinación de la Presión Sanguínea , Cafeína/farmacología , Estudios de Casos y Controles , Estimulantes del Sistema Nervioso Central/farmacología , Frío , Femenino , Humanos , Masculino , Músculo Esquelético/inervación , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/fisiopatologíaRESUMEN
Intake of coffee, one of the most common beverages worldwide, is often reported as a cardiovascular risk factor; however, definitive data are lacking. Acute intake of coffee or beverages containing caffeine can increase blood pressure, heart minute volumes, and cardiac index, as well as activate the sympathetic nervous system in nonhabitual coffee drinkers. Interestingly, this is not observed in habitual coffee drinkers. Restriction of coffee or caffeinated beverages is no longer indicated in the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines for the treatment of hypertension. In fact, no clear association between coffee and the risk of hypertension, myocardial infarction, or other cardiovascular diseases has been demonstrated. In contrast to early studies, recent research indicates that habitual moderate coffee intake does not represent a health hazard and may even be associated with beneficial effects on cardiovascular health.
Asunto(s)
Cafeína/efectos adversos , Sistema Cardiovascular/efectos de los fármacos , Café/efectos adversos , Glucemia/efectos de los fármacos , Cafeína/química , Cafeína/metabolismo , Café/química , Café/metabolismo , Culinaria/métodos , Diabetes Mellitus Tipo 1/prevención & control , Conducta de Ingestión de Líquido , Medicina Basada en la Evidencia , Humanos , Hiperlipidemias/inducido químicamente , Hipertensión/inducido químicamente , Resistencia a la Insulina , Fatiga Mental/prevención & control , Infarto del Miocardio/inducido químicamente , Infarto del Miocardio/prevención & control , Medición de Riesgo , Factores de RiesgoRESUMEN
BACKGROUND: Coffee is the most abundantly consumed stimulant worldwide. However, its cardiovascular safety remains controversial. Possible health hazards have been related to its main ingredient, caffeine. Activation of the sympathetic nervous system by coffee may enhance cardiovascular risk; however, it is unclear whether this effect of coffee is related to caffeine or other substance(s) also contained in decaffeinated coffee. METHODS AND RESULTS: In 15 healthy volunteers (6 habitual and 9 nonhabitual coffee drinkers) arterial blood pressure (BP), heart rate, and muscle sympathetic nervous activity (MSA) were continuously recorded before and after drinking a triple espresso or a decaffeinated triple espresso or after intravenous administration of caffeine (250 mg) or placebo (saline) in the same subjects. There was a significant time x condition interaction for the intravenous caffeine and placebo conditions for MSA, with caffeine showing a significant increase in MSA at 60 minutes (53.2+/-14.1% total activity) and the placebo group showing no effect. A similar significant time effect was found for coffee drinking (54.1+/-22.5% total activity). Habitual and nonhabitual coffee drinkers demonstrated similar changes in MSA and BP after intravenous caffeine, whereas coffee drinking increased BP in nonhabitual drinkers only, despite comparable increases of MSA and plasma caffeine levels. Nonhabitual coffee drinkers showed similar activation of MSA and BP after caffeine infusion, coffee, or decaffeinated coffee. CONCLUSIONS: Acutely, coffee and caffeine induced comparable increases in MSA and BP in nonhabitual coffee drinkers, whereas habitual coffee drinkers exhibited lack of BP increase despite MSA activation to coffee. Because decaffeinated coffee also increases BP and MSA in nonhabitual drinkers, ingredients other than caffeine must be responsible for cardiovascular activation.